Drugs / 608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04367441 | Nov 2019 → Oct 2020 | psoriasis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04367441 ↗ |
| Action | Inhibit | “anti-IL17A” NCT04367441 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-IL17A monoclonal antibody injection” NCT04367441 ↗ |
| Route | Subcutaneous | “following subcutaneous injection” NCT04367441 ↗ |
| Target | IL17A | “anti-IL17A” NCT04367441 ↗ |